Study Group: Drug Development Software Experts(?)
Council Members in this Study Group: 22
Request a survey with this Study Group
Leading Experts in this Study Group
![]() |
What is a GLG Leader? |
Eric Gruff, PhD MBAPrincipal
E4 Consulting
Eric Gruff, PhD, MBA, BS, is the Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 16 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...
Chairman
Health Systems Solutions Ltd
Roger Wallhouse is the Founder/Managing Partner at Health Systems Solutions Ltd, United Kingdom, a company providing strategic business services to healthcare organizations and focusing on market entry, company and product positioning, and governmental introductions. He has over 30 years of experience...
President and Chief Executive Officer
AciesHealth
Mark Capriani, MBA, is the President and Chief Executive Officer of AciesHealth, a specialty pharmaceutical company in Pennsylvania. He has over 15 years of experience in pharmaceutical industry including biotech, branded and multi source pharmaceuticals, consumer products, device, and wound and burn...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Experts(?)
Regardless of the reason (greed, carelessness, incompetence, etc.) that Chinese heparin became tainted, the end result will be increased scrutiny on imported raw materials and other ingredients, not only from China, but from all 3rd World suppliers. How the FDA and other regulatory agencies actually...
The 3-month reduction in HbA1c demonstrated by AGI-1067 is promising, but I still have many questions regarding the design and outcomes. There are many existing therapies that lower A1c - many have undesireable side effects like weight gain or hepatotoxicity.
The news that Cubist's Cubicin has been contaminated with 2-mercaptobenzothiazole (MBT) has caused great concern for patients. It appears that the MBT has leeched out of the Cardinal Health ReadyMED drug pumps that are used for delivering Cubicin. Regardless of who is at fault, everyone involved (Cubist,...
The pharmaceutical industry continues to lay its collective head on the chopping block by pushing drugs like Vytorin that demonstrate at best marginal activity. Insurers have a fiduciary duty to push back against the poor judgement of drugmakers who take advantage of confusion and DTC advertising to...
While disappointing for patients and caregivers, Pfizer's loss of a late-stage treatment for melanoma casts an even darker shadow on the ability of pharmaceutical and biotech companies to successfully bring new treatments to market. Coupled with other recent Phase 3 failures, this latest outcome points...
Most Common Company Types:
- Pharmaceutical Software, IT & Other
- Consultancy, Pharma-Focused
- Pharmaceuticals/Biotechnology Research Services
- Pharmaceuticals Manufacturer
- Biotechnology Manufacturer
- Academic Institution*
- Individual/Small Consultancy
- Other Healthcare Information Technology Company
- Strategic Management
Most Common Job Types:
- Director
- President
- Owner
- Engineer
- Product/Brand Director
- System Engineer
- Manufacturing Director
- Quality Control Supervisor
- Chief Executive Officer
- IT Manager
- Principal
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms


